Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Apricus Biosciences (APRI) Presents at Rodman & Renshaw Conference

Apricus Biosciences, Inc. (NASDAQ: APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. The company has initiated a phase IIb trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions in the future. Apricus’s lead commercial product, Vitaros®, is currently approved in Europe and Canada for the treatment of erectile dysfunction and is being commercialized in several European markets. For more information, visit the company’s website at

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.